Merry Life Biomedical Advances TML-6 Into Global Phase 2 Study for Early Alzheimer’s Disease

Merry Life Biomedical has announced that TML-6, an investigational oral treatment developed in Taiwan for early Alzheimer's disease, has advanced into a global Phase 2 clinical study.

The study will be conducted across Taiwan, Sweden, and the United States.

A total of 20 clinical sites will participate in the study. This includes nine medical centers in Taiwan, seven sites in Sweden, and four centers in the United States.

The trial is expected to enroll approximately 210 people with early Alzheimer's disease.

TML-6 is still an investigational treatment. Its effectiveness and safety for treating Alzheimer's disease have not yet been established.

Why Researchers Are Looking for New Approaches to Alzheimer's

Alzheimer's disease is a progressive brain disorder that affects memory, thinking, and everyday functioning.

The disease is linked to abnormal changes in the brain, including the buildup of amyloid plaques and tau tangles.

Amyloid is a protein that can collect between brain cells, while tau can form abnormal tangles inside nerve cells.

Some recently approved Alzheimer's treatments are designed to remove amyloid from the brain. Clinical studies have shown that removing amyloid can slow clinical decline in people with early Alzheimer's disease.

However, these treatments do not stop the disease completely.

Researchers are therefore continuing to investigate other biological processes that may contribute to the progression of Alzheimer's disease.

TML-6 Takes a Different Biological Approach

TML-6 is being studied through an approach that focuses on the autophagy-lysosomal pathway.

This pathway is part of the body's natural cellular cleaning system.

In simple terms, cells need a way to identify, break down, and recycle damaged proteins and other unwanted material. The autophagy-lysosomal system helps perform this job.

Researchers believe that problems with this cellular cleanup process may contribute to the loss of normal function in brain cells.

Merry Life Biomedical is studying whether TML-6 can influence this pathway and potentially support the ability of neurons and other brain cells to handle damaged cellular material.

What Is the Autophagy-Lysosomal Pathway?

The autophagy-lysosomal pathway is a system cells use to remove and recycle unwanted or damaged material.

Think of it as part of the cell's internal waste-management system.

When this process does not work properly, damaged proteins and other cellular components can accumulate.

In Alzheimer's disease, researchers are studying whether problems with cellular cleanup may be connected with amyloid-related changes, oxidative stress, inflammation, and damage to neurons.

TML-6 is being investigated to understand whether targeting this biology can have an effect on disease-related processes.

Preclinical Research Supported Further Development

Before entering Phase 2, TML-6 was studied in preclinical research.

These studies examined its effects on autophagy and lysosomal function in neurons and microglia.

Microglia are immune cells in the brain that help protect the nervous system and remove damaged material.

Researchers also examined TML-6 in relation to amyloid-related pathology, oxidative stress, and inflammation.

These laboratory and preclinical findings provided part of the scientific basis for moving the program into further clinical development.

The Phase 2 study will now provide human clinical data that can help determine whether the approach translates into measurable benefits for patients.

Global Phase 2 Study Will Enroll About 210 Patients

The Phase 2 study is randomized, double-blind, and placebo-controlled.

These study designs are commonly used in clinical research to reduce bias when comparing an investigational treatment with placebo.

Approximately 210 participants with early Alzheimer's disease will take part.

Participants will receive either TML-6 at a dose of 100 mg, TML-6 at 200 mg, or placebo.

The treatment will be taken once daily for 52 weeks.

Researchers will compare the groups to determine whether TML-6 produces changes in clinical measures and biological markers associated with Alzheimer's disease.

The Main Study Measure Is Cognition and Daily Function

The primary endpoint of the study is the change from baseline in the Clinical Dementia Rating Sum of Boxes, or CDR-SB.

The CDR-SB is a clinical tool used to assess the severity of dementia.

It looks at areas such as memory, orientation, judgment, problem-solving, personal care, and the ability to function in everyday life.

By measuring changes over the course of the study, researchers can assess whether participants receiving TML-6 experience a different rate of clinical decline compared with those receiving placebo.

Blood Biomarkers Will Also Be Studied

The study will also examine several blood-based biomarkers.

These include p-Tau 217, amyloid-beta, GFAP, and NfL.

p-Tau 217 is a biomarker associated with tau-related changes in Alzheimer's disease.

Amyloid-beta measurements can provide information about amyloid-related disease biology.

GFAP is a marker associated with changes involving astrocytes, which are support cells in the brain.

NfL, or neurofilament light chain, can provide information about nerve cell damage.

These measurements may help researchers understand what is happening biologically in patients receiving TML-6.

International Alzheimer's Experts Are Joining the Program

The global study brings together researchers from different countries and areas of Alzheimer's research.

Henrik Zetterberg, M.D., Ph.D., will support blood biomarker analysis.

Barbara B. Bendlin, Ph.D., will contribute expertise in amyloid PET and MRI imaging.

PET imaging can be used to study changes in the brain, while MRI provides detailed images of brain structure.

Gary W. Small, M.D., is serving as a global medical consultant.

Jacobo Mintzer, M.D., is advising on global clinical site execution.

The involvement of researchers with experience in biomarkers, imaging, and clinical trials is intended to support the international Phase 2 program.

Sweden Brings Experience in Alzheimer's Clinical Trials

Seven Swedish clinical sites are participating in the study.

The Swedish program is being conducted with Anne Börjesson-Hanson, M.D., Ph.D., of Karolinska Institute and Karolinska University Hospital.

Dr. Börjesson-Hanson has experience working on international Alzheimer's clinical trials, including studies involving disease-modifying treatments.

Her experience includes work in clinical trial network development and participation as a principal investigator in more than 40 global clinical trials.

She has also held leadership roles in international Alzheimer's research programs.

Swedish and Taiwanese Researchers Will Work Together

The TML-6 program is also creating closer collaboration between researchers in Sweden and Taiwan.

On October 4, Dr. Börjesson-Hanson is scheduled to visit Taiwan for the Taiwan Dementia Society Annual Scientific Meeting.

She will give a plenary lecture and meet with the nine Taiwanese principal investigators participating in the TML-6 study.

The meeting is expected to provide an opportunity for investigators from the different participating countries to discuss the clinical development program.

Nine Taiwanese Medical Centers Are Participating

Taiwan has nine medical centers participating in the global Phase 2 trial.

This makes Taiwan the largest group of participating clinical sites within the study.

For Merry Life Biomedical, the participation of multiple Taiwanese medical centers is also significant because TML-6 was developed in Taiwan.

The company said the program provides an opportunity for a Taiwan-developed therapeutic candidate to participate in global Alzheimer's research.

The Study Could Provide Important Clinical Data

The move into Phase 2 represents a change in the development stage of TML-6.

Earlier clinical development primarily focuses on questions such as safety, tolerability, and how the body processes an investigational medicine.

A Phase 2 study begins to look more closely at whether the treatment may provide a clinical benefit.

For TML-6, researchers will be able to examine clinical outcomes alongside blood biomarkers and imaging data.

This combination could provide a more detailed picture of how the treatment affects patients and disease-related biology.

What Merry Life Biomedical Plans After Phase 2

Merry Life Biomedical views the global Phase 2 study as an important stage in the development of TML-6.

Depending on the study's progress and the data generated, the company plans to evaluate the next steps toward Phase 3 development.

Phase 3 studies are generally larger clinical trials designed to provide additional evidence of a medicine's effectiveness and safety before regulatory applications.

The company has not yet provided a specific Phase 3 design or timeline.

Those decisions will depend on the Phase 2 results and the regulatory strategy for the program.

Company Explores Partnerships and Funding

Merry Life Biomedical is also looking for potential partners and additional sources of funding to support the future development of TML-6.

The company said it is exploring strategic investment, international venture capital, capital-market financing, and partnerships with pharmaceutical companies.

It is also discussing potential licensing and co-development arrangements with international pharmaceutical and strategic partners.

Depending on the Phase 2 results and regulatory plans, these discussions could include licensing, co-development, or other partnership structures.

For now, TML-6 remains in clinical development, with the global Phase 2 study expected to generate the next major set of clinical and biological data for the program.